Jump to Header Jump to Main Content Jump to Footer

A Pilot Pembrolizumab Combined w/Stereotactic Ablative Radiotherapy for Pts w/Adv or Met Sarcoma

Jeremy Phillip Harris


A Study On:

  • Bones and Joints
  • Kaposi's Sarcoma
  • Soft Tissue

Status:

  • Open

Eligibility

Adults

Interested in joining this trial?

Official Title

A Single-Arm Pilot Study of Pembrolizumab Combined with Stereotactic Ablative Radiotherapy for Patients with Advanced or Metastatic Sarcoma

Details

The purpose of this research study is to test if a combination of two treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT), can delay tumor growth in patients with cancers that develop in their soft tissues (sarcomas).


Eligibility

You can join if...

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you satisfy the following criteria:

  • are at least 18 years of age or older
  • have been diagnosed with soft tissue sarcoma
  • are not a candidate for surgery based on your doctor’s assessment

Exclusion Requirements

You cannot participate in this study if you satisfy the following criteria:

  • are pregnant or nursing
  • are receiving any other investigational agents

Get in touch with our study team